Coeliac disease; Gluten intolerance; Lactose intolerance; Fructose intolerance; Symptoms started mild with the first doses and in the second they were intensified until today; rectal bleeding; chronic swelling; Nodules are still present; Severe pain in stomach (epigastric); Migraines; pain in the joints; Lymphatic nodule reactive (supraclavicular, lung and armpits).; petechiae in the mouth; This is a spontaneous report received from contactable reporter(s) (Other HCP). The reporter is the patient.  A 36-year-old female patient (not pregnant) received bnt162b2 (BNT162B2), on 18Jan2021 as dose 2, single (Lot number: EK4176) at the age of 33 years intramuscular, in left arm for covid-19 immunisation. The patient's relevant medical history was not reported. There were no concomitant medications. Vaccination history included: bnt162b2 (DOSE 1, SINGLE, Batch/Lot No: EK5730, Location of injection: Arm Left, Route of Administration: Intramuscular), administration date: 29Dec2020, for COVID-19 immunization, reaction(s): "rectal bleeding", "chronic swelling  (Swelling)", "Nodules", "Severe pain in stomach (epigastric)", "Migraines", "pain in the joints", "Lymphatic nodule reactive (supraclavicular, lung and armpits)", "petechiae in the mouth", "Gluten intolerance", "Lactose intolerance", "Fructose intolerance". The following information was reported: LYMPHADENOPATHY (disability) with onset Jan2021, outcome "not recovered", described as "Lymphatic nodule reactive (supraclavicular, lung and armpits)."; MIGRAINE (disability) with onset Jan2021, outcome "not recovered", described as "Migraines"; NODULE (disability) with onset Jan2021, outcome "not recovered", described as "Nodules are still present"; ABDOMINAL PAIN UPPER (disability) with onset Jan2021, outcome "not recovered", described as "Severe pain in stomach (epigastric)"; CONDITION AGGRAVATED (disability) with onset Jan2021, outcome "not recovered", described as "Symptoms started mild with the first doses and in the second they were intensified until today"; SWELLING (disability) with onset Jan2021, outcome "not recovered", described as "chronic swelling"; ARTHRALGIA (disability) with onset Jan2021, outcome "not recovered", described as "pain in the joints"; MOUTH HAEMORRHAGE (disability) with onset Jan2021, outcome "not recovered", described as "petechiae in the mouth"; RECTAL HAEMORRHAGE (disability) with onset Jan2021, outcome "not recovered", described as "rectal bleeding"; COELIAC DISEASE (disability), outcome "unknown"; GLUTEN SENSITIVITY (disability), outcome "unknown", described as "Gluten intolerance"; LACTOSE INTOLERANCE (disability), outcome "unknown"; FRUCTOSE INTOLERANCE (disability), outcome "unknown". The events "rectal bleeding", "chronic swelling", "nodules are still present", "severe pain in stomach (epigastric)", "migraines", "pain in the joints", "lymphatic nodule reactive (supraclavicular, lung and armpits).", "petechiae in the mouth", "coeliac disease", "gluten intolerance", "lactose intolerance", "fructose intolerance" and "symptoms started mild with the first doses and in the second they were intensified until today" required physician office visit and emergency room visit. The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (Apr2020) Negative, notes: Nasal Swab. Therapeutic measures were taken as a result of rectal haemorrhage, swelling, nodule, abdominal pain upper, migraine, arthralgia, lymphadenopathy, mouth haemorrhage, condition aggravated.  Clinical course: The after 2 years of celiac disease with gluten, lactose and fructose intolerance. Currently ruled out for hodgkin's lymphoma. The symptoms started mild with the first doses and in the second they were intensified until today. Patient had never gotten COVID (the disease). Test/medication IV and oral were taken. Known allergies: Gluten, lactose and fructose. These intolerances were developed after the Covid Vaccine.; Sender's Comments: Based on the current available limited information in the case provided, the causal association between the events Rectal hemorrhage, Swelling, Nodule, Abdominal pain upper, Migraine, Mouth hemorrhage, Coeliac disease, Gluten sensitivity, Lactose intolerance, Fructose intolerance, Condition aggravated and the use of suspect product cannot be fully excluded. Based on known drug safety profile, the events of Arthralgia, Lymphadenopathy, are assessed as related to suspect product. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.,Linked Report(s) : PR-PFIZER INC-202300361826 same reporter/patient different dose number;